Canaccord raised the firm’s price target on Generation Bio (GBIO) to $10 from $9 and keeps a Buy rating on the shares. The firm said the company update included 2 key announcements. First, it announced new NHP data that shows siRNA delivery to T cells via the company’s proprietary ctLNP platform; likely the first dataset of its kind. And also noted that it has developed siRNA candidates targeting LAT1 and VAV1, known targets in the autoimmune space.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GBIO:
- Generation Bio Co. Warns Stakeholders of Persistent Business Risks in 2024 Report
- Generation Bio’s Promising siRNA Delivery and Financial Stability Justify Buy Rating Despite Workforce Reductions
- Wedbush downgrades Generation Bio as company seeks strategic alternatives
- Generation Bio downgraded to Neutral from Outperform at Wedbush
- Generation Bio Co. Reports Promising Data and Financial Results